Get started
BRIDGEBIO PHARMA INCBRIDGEBIO PHARMA INCBRIDGEBIO PHARMA INC

BRIDGEBIO PHARMA INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Bonds

1BBIO chart


Full chart

1BBIO upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.55 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.26 EUR
Net income (FY)
‪−517.53 M‬ EUR
Revenue (FY)
‪214.35 M‬ EUR
Shares float
‪160.74 M‬
Beta (1Y)
0.92

Employees


Employees (FY)
730
Change (1Y)
+180 +32.73%
Revenue / Employee (1Y)
‪293.63 K‬ EUR
Net income / Employee (1Y)
‪−708.95 K‬ EUR

About BridgeBio Pharma, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Neil Kumar
Website
bridgebio.com
Headquarters
Palo Alto
Founded
2015
FIGI
BBG01TNWLS59
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1BBIO news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

1BBIO highest yielding bonds


BBIO5355568
BridgeBio Pharma, Inc. 2.25% 01-FEB-2029
Yield to maturity
5.81%
Maturity date
Feb 1, 2029
US10806XAH5
BRIDGEBIO PH 25/31CV 144A
Yield to maturity
1.69%
Maturity date
Mar 1, 2031
BBIO5151039
BridgeBio Pharma, Inc. 2.5% 15-MAR-2027
Yield to maturity
−3.68%
Maturity date
Mar 15, 2027

See all 1BBIO bonds 


Check out other big names from the same industry as 1BBIO.

Frequently Asked Questions


The current price of 1BBIO is 29.23 EUR — it has decreased by −0.24% in the past 24 hours. Watch BRIDGEBIO PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BRIDGEBIO PHARMA INC stocks are traded under the ticker 1BBIO.
1BBIO stock has fallen by −0.61% compared to the previous week, the month change is a −6.73% fall, over the last year BRIDGEBIO PHARMA INC has showed a −6.73% decrease.
We've gathered analysts' opinions on BRIDGEBIO PHARMA INC future price: according to them, 1BBIO price has a max estimate of 84.47 EUR and a min estimate of 32.90 EUR. Watch 1BBIO chart and read a more detailed BRIDGEBIO PHARMA INC stock forecast: see what analysts think of BRIDGEBIO PHARMA INC and suggest that you do with its stocks.
1BBIO reached its all-time high on Apr 30, 2025 with the price of 34.42 EUR, and its all-time low was 28.90 EUR and was reached on May 22, 2025. View more price dynamics on 1BBIO chart.
See other stocks reaching their highest and lowest prices.
1BBIO stock is 0.24% volatile and has beta coefficient of 0.92. Track BRIDGEBIO PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is BRIDGEBIO PHARMA INC there?
Today BRIDGEBIO PHARMA INC has the market capitalization of ‪5.42 B‬, it has decreased by −2.01% over the last week.
Yes, you can track BRIDGEBIO PHARMA INC financials in yearly and quarterly reports right on TradingView.
BRIDGEBIO PHARMA INC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
1BBIO earnings for the last quarter are −0.81 EUR per share, whereas the estimation was −0.85 EUR resulting in a 4.13% surprise. The estimated earnings for the next quarter are −0.70 EUR per share. See more details about BRIDGEBIO PHARMA INC earnings.
BRIDGEBIO PHARMA INC revenue for the last quarter amounts to ‪107.81 M‬ EUR, despite the estimated figure of ‪55.61 M‬ EUR. In the next quarter, revenue is expected to reach ‪80.81 M‬ EUR.
1BBIO net income for the last quarter is ‪−154.76 M‬ EUR, while the quarter before that showed ‪−256.03 M‬ EUR of net income which accounts for 39.56% change. Track more BRIDGEBIO PHARMA INC financial stats to get the full picture.
No, 1BBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has 730 employees. See our rating of the largest employees — is BRIDGEBIO PHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRIDGEBIO PHARMA INC EBITDA is ‪−627.77 M‬ EUR, and current EBITDA margin is −257.45%. See more stats in BRIDGEBIO PHARMA INC financial statements.
Like other stocks, 1BBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRIDGEBIO PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.